尤瑞克林不良反应文献分析及临床应用监护流程  

Literature Analysis of Adverse Drug Reactions Caused by Urinary Kininogenase and Clinical Application Monitoring Process

作　　者：柴东燕[1,3] 徐成阳 阚亦菲 赵成龙 张楠楠[3] 马培志 乔利景[4] 王艳玲 段红艳 CHAI Dongyan;XU Chengyang;KAN Yifei;ZHAO Chenglong;ZHANG Nannan;MA Peizhi;QIAO Lijing;WANG Yanling;DUAN Hongyan(Department of Pharmacy,Henan Provincial People’s Hospital,Zhengzhou 450003;Department of General Practice,Henan Provincial People’s Hospital,Zhengzhou 450003,China;International Medical Center of Henan Province,Zhengzhou 450003,China;Department of Pharmacy,Ningling County Hospital of Traditional Chinese Medicine,Shangqiu 476700,China)

机构地区：[1]河南省人民医院药学部,河南郑州450003 [2]河南省人民医院全科医学科,河南郑州450003 [3]河南省国际医疗中心,河南郑州450003 [4]宁陵县中医院药学部,河南商丘476700

出　　处：《河南医学研究》2023年第12期2140-2144,共5页Henan Medical Research

基　　金：中国药学会全国医药信息网2021年科普研究项目[CMEI2021KPYJ(JZYY)00217];河南省医学科技攻关计划(软科学)项目(RKX202202016)。

摘　　要：目的探讨尤瑞克林临床应用过程中存在的用药风险点,制定全程化药品风险防范措施。方法以“尤瑞克林”“不良反应”“安全性”和“过敏性休克”等为关键词,检索中国生物医学文献数据库、中国期刊全文数据库、中文科技期刊数据库、中华医学期刊全文数据库、中国知网、维普网及万方数据库中2005年5月至2022年5月报道的涉及尤瑞克林注射液不良反应的案例报道,按纳入与排除标准共纳入10篇案例报道,进行资料提取和统计分析,并梳理临床用药过程中的风险点。结果5篇为系列报道,5篇为个案报道,其中涉及男性10例,女性6例,不详7例;年龄45~80岁,平均(63.75±8.59)岁;Ⅰ级不良反应6例(26.09%),Ⅱ级5例(21.74%),Ⅲ级3例(13.04%),Ⅳ级9例(39.13%)。在Ⅳ级不良反应中,发生在首次用药和在输注开始的前10 min内的占比均为88.89%(8例)。结论成立多学科临床团队,制定尤瑞克林注射液临床应用监护流程,更加系统地减少药物不良反应的发生。Objective To explore the medicine risk points in the clinical application of urinary kininogenase,and develop preventive measures for the whole-process clinical application.Methods Based on such key words“urinary kininogenase”“adverse reactions”“safety”and“anaphylactic shock”,case reports were searched for that was related to the adverse reactions caused by urinary kininogenase reported in Chinese biomedical literature database,Chinese journal full text database,Chinese scientific and technological journal database,Chinese medical journal full text database,CNKI,VIP and Wanfang databases from May 2005 to May 2022.According to the inclusion and exclusion criteria,10 articles were included for data retrieval and statistical analysis.And sort out the risk points in the clinical medication process.Results A total of 5 series reports and 5 case reports were searched,including 10 males and 6 females,45 to 80 years old,with a mean of(63.75±8.59)years old.There were 6 cases(26.09%)of gradeⅠadverse reactions,5 cases(21.74%)of gradeⅡ,3 cases(13.04%)of gradeⅢand 9 cases(39.13%)of gradeⅣ.Among the gradeⅣadverse reactions,the proportion of occurring in the first infusion and during the first 10 minutes was 88.89%(8 cases).Conclusion A multidisciplinary clinical team was established to develop the clinical application monitoring process of urinary kininogenase injection,to reduce the occurrence of adverse drug reactions more systematically.

关 键 词：尤瑞克林 药品不良反应 用药安全 监护流程 

分 类 号：R972[医药卫生—药品]